Allos Therapeutics to Host Analyst and Investor Briefing on Monday, December 8, 2008
December 03 2008 - 7:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on developing and commercializing innovative small molecule
drugs for the treatment of cancer, today announced that it will
host an analyst and investor briefing in conjunction with the 50th
Annual Meeting of the American Society of Hematology (ASH) from
6:00 p.m. to 8:00 p.m. (Pacific) on Monday, December 8, 2008.
Members of the Company�s senior management will provide a corporate
overview. In addition, key investigators from the Company�s pivotal
Phase 2 PROPEL trial in patients with relapsed or refractory
peripheral T-cell lymphoma will review top line results from the
trial. The event will be webcast and may be accessed through a link
posted on the Allos website home page and investor relations
section. The webcast will be available for replay on Allos� website
through December 19, 2008. About Allos Therapeutics, Inc. Allos
Therapeutics is a biopharmaceutical company focused on developing
and commercializing innovative small molecule drugs for the
treatment of cancer.�The Company's lead product candidate,
pralatrexate (PDX), is a novel antifolate currently under
evaluation in a pivotal Phase 2 (PROPEL) trial in patients with
relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial
is being conducted under an agreement reached with the U.S. Food
and Drug Administration under its special protocol assessment, or
SPA process. The Company is also investigating pralatrexate in
patients with non-small cell lung cancer, bladder cancer and a
range of lymphoma sub-types.�The Company's other product
candidate�is RH1, a targeted chemotherapeutic agent currently being
evaluated in a Phase 1 trial in patients with advanced solid tumors
or non-Hodgkin�s lymphoma (NHL). The Company currently retains
exclusive worldwide rights to pralatrexate and RH1 for all
indications. For additional information, please visit the Company�s
website at www.allos.com. Safe Harbor Statement The anticipated
presentation will contain forward-looking statements that involve
significant risks and uncertainties. Additional information
concerning these forward-looking statements and other factors that
may cause actual results to differ materially from those
anticipated in the forward-looking statements is contained in the
"Risk Factors" section of the Company's Annual Report on Form 10-K
for the year ended December 31, 2007 and in the Company's other
periodic reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the
presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics, Inc. News Articles